

# Results of Organ-Sparing Treatment of Muscle-Invasive Urothelial Carcinoma

Vladimir Startsev

State paediatrics medical university

## ABSTRACT

In 2018 newly diagnosed urothelial carcinoma (UC) in Russia were registered in 14,446 cases, including 26% pts in stage III-IV. Thus, for every fourth Russian, UC is first detected in a neglected stage. Due to the Guidelines EAU-2017, cystectomy or alternative therapy with bladder preservation used in the treatment of such patients. Chemotherapy in UC pts (M-VAC, GC and other's) is accompanied with side effects (myelosuppression, dyspepsia, neurolegia, etc.) that reduce the patient's QoL and, thus, the effectiveness of therapy.

**PURPOSE.** To evaluate the effectiveness of regional (i/arterial) ChTer based on platinum drugs in patients with locally advanced UC.

**MATERIALS AND METHODS.** We evaluated the results of regional ChTer in 36 patients with UC in stages T3a-4N0-1M0G2-3 (8 women, 28 males in median age 65,4±4,2 y.o.) in 1998- 2003 III. Earlier 21 pts received organ-preserving treatment (TURB + neoadjuvant / adjuvant ChTer), with a short clinical effect. All the patients after the catheterization and angiography of the uroperitoneal arteries received courses (from 6 to 36, median 18) of the regional ChTer (cisplatin, 50 mg / m<sup>2</sup> and adriablastin, 20 mg / m<sup>2</sup>) and metostrexate (20 mg / m<sup>2</sup>) + vinblastine (0, 7 mg / m<sup>2</sup>) intravenously, by the standard MVAC courses. After finishing of ChTer, the main group of pts was observed during 12-60 months (average 28 months) and over the next 10 years they were studied for their overall survival by a prospective study method.

**RESULTS.** Long-term use of regional ChTer with standard three-week interruptions contributed to partial and complete tumor response in 22 (61.1%) cases. During 24 months after ChTer there were no signs of tumor growth in the bladders of 13 (26.9%) pts. The effect of the treatment was determined by Grade, tumor Stage, the presence of N+ and the previous oncological anamnesis.

## Biography

Vladimir Startsev is the active member of the European Association of Urology and European Society of Surgical Oncology (since 2002), Russian Society of Urologists (since 2001), Russian Association of Oncological Urologists (since 2003) and Professional Association of Russia Anthologists (since 2005). He is also the Professor of the State paediatric medical university (St.-Petersburg, Russia). Corresponding member of Russian Academy of Natural history

(Moscow). He also got the Doctoral Degree (MSc) in "Public health and health care" (2007, approved in 2008). He is also the Founder, business coach and chief manager of the Prime Medical Business Academy (St.-Petersburg, Russia) and experienced manager in In-patient's care: start-up and management of the new department in regional medical institution (chief manager of the surgical dept., 4.5 years..

**Citation:** Vladimir Startsev: Results of Organ-Sparing Treatment of Muscle-Invasive Urothelial Carcinoma, Webinar on Cancer Therapy 2021, May 26, 2021.

**Copyright:** © 2021. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.